Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia
Information source: University of Malaya
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Airway Response
Intervention: alfentanil (Drug)
Phase: N/A
Status: Recruiting
Sponsored by: University of Malaya Official(s) and/or principal investigator(s): Lee Chew Kiok, MBBS, Principal Investigator, Affiliation: Department of Anaesthesiogy, UMMC.
Overall contact: Lee Chew Kiok, MBBS, Phone: 0162737229, Email: cklee1127@yahoo.com
Summary
This study aims to determine the optimal dose of alfentanil in suppressing the airway
reflexes during supreme LMA removal in anaesthetized adult.
Clinical Details
Official title: Optimal Dose of Alfentanil for Removal of Supreme Laryngeal Mask Airway During Emergence From Desflurane Anaesthesia
Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor)
Primary outcome: Optimal dose of alfentanil for successful LMA removal in spontaneously breathing anaesthetized adults
Secondary outcome: Nunber of patient with airway complication
Detailed description:
The removal of LMA may be associated with coughing, biting, agitation and airway
complication such as laryngospasm. Thus it is advisable to remove the LMA when the patient
is breathing spontaneously and when the airway reflexes are still depressed. A number of
techniques have been used to prevent this adverse emergence phenomenon, such as removing the
tube while the patient is in deep plane of anaesthesia or administration of local
anaesthetic and intravenous opioids
The administration of intravenous opioids before emergence may be useful for preventing
cough, agitation and hemodynamic response. Alfentanyl is proven to suppress cough and
agitation during the endotracheal tube emergence. However, its use in suppressing cough in
LMA patient has not been evaluated.
Eligibility
Minimum age: 18 Years.
Maximum age: 49 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
1. ASA I and II patients
2. Age 18 to 49 years old
3. Minor elective day care surgery (> 20 minute and less than 2 hours) which require
local anaesthetic infiltration and does not require use of long acting opioids.
Exclusion Criteria:
1. Potential difficult airway
2. Reactive airway disease or sign and symptoms of upper respiratory tract infection.
3. History of cardiac, pulmonary and renal diseases
4. Body Mass Index > 30 kgm2.
5. Risk of aspiration.
6. Poor dentition with high risk of damage.
7. Patient refusal.
Locations and Contacts
Lee Chew Kiok, MBBS, Phone: 0162737229, Email: cklee1127@yahoo.com
University Malaya Medical Centre, Lembah Pantai, Kuala Lumpur 59100, Malaysia; Recruiting Lee Chew Kiok, MBBS, Phone: 0162737229, Email: cklee1127@yahoo.com Wang Chew Yin, Phone: 0192340232, Email: wangcy1836@gmail.com Lee Chew Kiok, MBBS, Principal Investigator
Additional Information
Starting date: February 2011
Last updated: June 10, 2011
|